指南与共识肝病消化道出血消化内镜

Baveno VIII 共识:门静脉高压管理进展

Baveno VIII - Advancing consensus in portal hypertension.
指南 / 共识 · J Hepatol · 2026-08-20

Baveno VIII 共识会议于2026年3月在意大利Baveno举行,基于结构化共识流程,由九个专家组对晚期慢性肝病、门静脉高压和血管性肝病的关键领域进行证据回顾与投票,强共识定义为超过80%的教师同意。共272条声明和建议达成强共识,涵盖代偿期ACLD无创风险分层、脂肪性肝病修饰因素、首次和进一步失代偿预防、门静脉高压出血管理、肝硬化再代偿及血管性肝病,并新增儿科患者指导。

要点

  • Baveno VIII更新了代偿期ACLD无创风险分层及CSPH相关诊断与预后截断值。
  • 共识涵盖首次和进一步失代偿预防、门静脉高压出血管理及肝硬化再代偿。
  • 新增儿科患者指导,并保留未修订的HVPG测量等既往推荐。

核心结论

  • Baveno VIII在Baveno VII基础上更新了晚期慢性肝病、门静脉高压和血管性肝病的临床指导,共272条声明和建议达成强共识。

研究设计与样本

  • Baveno VIII共识会议于2026年3月在意大利Baveno举行,由Baveno Cooperation与VALDIG合作召集专家组。
  • 采用结构化共识流程,九个专家组对证据进行迭代回顾并在教师中投票,强共识定义为超过80%的教师同意。

主要发现

  • 共272条声明和建议达成强共识,覆盖代偿期ACLD无创风险分层、脂肪性肝病修饰因素、失代偿预防、门静脉高压出血管理、肝硬化再代偿及血管性肝病。
  • 血管性肝病包括Budd-Chiari综合征、PSVD或NCPF及PVT;CSPH的核心地位和非侵入性检测的扩展使用被重申,若干诊断和预后截断值被修订。
  • Baveno VIII新增对儿科患者的选定指导;未在Baveno VIII中特别修订的既往推荐(如HVPG测量)仍然有效。
  • 提出了识别153个优先主题的研究议程。

关键数值与推荐

  • 强共识定义为超过80%的教师同意。
  • 共272条声明和建议达成强共识。
  • 研究议程识别153个优先主题。

临床怎么用

  • 临床可依据Baveno VIII共识更新对晚期慢性肝病、门静脉高压和血管性肝病患者的风险分层与管理。
  • 应关注CSPH的核心地位及非侵入性检测的扩展应用,并参考修订后的诊断与预后截断值。
  • 既往未修订的推荐(如HVPG测量)仍然有效,可继续沿用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Baveno VIII - Advancing consensus in portal hypertension. J Hepatol. 2026. PMID: 42624290. doi:10.1016/j.jhep.2026.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。